Insulin Dextrose Infusion vs Nebulized Salbutamol vs Combination of Salbutamol and Insulin Dextrose in Acute Hyperkalemia

Hyperkalemia Clinical Trial

— InSaKa  

Official title:

InSaKa Trial: Insulin Dextrose Infusion Versus Nebulized Salbutamol Versus Combination of Salbutamol and Insulin Dextrose in Acute Hyperkalemia: a Randomized Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04012138
• Other study ID #: RC19_0048
• Status: Recruiting
• Phase: Phase 4
• Start date: December 20, 2019
• Est. completion date: June 20, 2026

Study information

• Verified date: April 2024
• Source: Nantes University Hospital
• Contact: Emmanuel MONTASSIER
• Phone: 02 53 48 20 38
• Email: emmanuel.montassier[@]chu-nantes.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Hyperkalemia is a common electrolyte disorder, especially among patients with chronic kidney disease, diabetes mellitus, or heart failure. Globally, the reported incidence of hyperkalemia varies from 1.1 to 10 per 100 hospitalizations, depending on the patient cohort and comorbidities. Hyperkalemia is a potentially life-threatening electrolyte disturbance that can be fatal if left untreated. Several studies have established the association between hyperkalemia and all-cause mortality. Because of the deleterious cardiac effects of hyperkalemia, its management is an emergency intervention. However, robust evidence is lacking to guide the emergency management of patients with hyperkalemia. Emergency treatment approaches are largely based on small studies, anecdotal experience, and traditionally accepted practice patterns within institutions. Therefore, a rigorous evaluation of the first-line treatments of hyperkalemia in emergency departments is needed and a large scale randomized clinical trial is warranted before robust recommendations for clinical practice can be made. Our clinical trial will improve the safety of patients with acute hyperkalemia and will help clinicians in their day by day practice to choose the treatment that significantly reduces morbidity and mortality during acute hyperkalemia management. Our results will be delivered in a timely fashion, owing to the high prevalence of hyperkalemia in the emergency department setting and to the commitment of the INI-CRCT network of Excellence, along with ED specialists used to work jointly.

the primary objective of our trial is to compare insulin/dextrose intravenous infusion, nebulized salbutamol or combination of nebulized salbutamol and insulin/dextrose intravenous infusion to reduce serum potassium concentration at 60 minutes, as first-line treatment, in emergency departments.

Description:

InSaKa trial is a therapeutic, controlled, open label, with parallel groups of treatment in a 1:1:1 ratio, multi-centre, national and randomized clinical trial to compare insulin/dextrose intravenous infusion, nebulized salbutamol or combination of salbutamol and insulin/dextrose to reduce serum potassium levels at 60 minutes. Eligible patients will be recruited in the emergency department and included in the study after testing for inclusion and non-inclusion criteria. Patients will be eligible for the randomization if they had a serum potassium concentration superior or equal to 6 mmol per liter. Randomization, which will be performed centrally, will be stratified 1) according to the serum potassium level at baseline of the initial treatment phase (6 to < 6.5 mmol per liter [moderate hyperkalemia] AND superior or equal to 6.5 mmol per liter [severe hyperkalemia]), and 2) according to the prescription or not of intravenous diuretics during the 6 previous hours. The protocol will be approved by the ethical committee (random allocation) of the IRB. All patients will provide written informed consent and the study will be performed in accordance with the International Conference on Harmonization Guidelines for Good Clinical Practice. All electrocardiograms will be read at a core electrocardiographic laboratory. At the time of screening, patients who meet all the inclusion and do not have non-inclusion criteria will be assigned to one of the 3 groups of treatment. The serum potassium will be then measured at 60 minutes. If the patient still has hyperkalemia at 60 minutes, the patient will be re-administered a treatment, left at the discretion of the physician in charge. This treatment might include insulin/dextrose intravenous infusion, nebulized salbutamol, the combination of nebulized salbutamol and insulin/dextrose intravenous infusion, bicarbonate, diuretics or dialysis. Especially, bicarbonate should be prescribed in case of metabolic acidosis or hypovolemic shock, and diuretics in case of acute heart failure. Importantly, if the patient has a major cardiovascular event before 60 minutes, all these treatments might be prescribed at the discretion of the physician in charge, if the clinical situation requires one or more of these therapeutic options, and based on up-to-date clinical practice guidelines and recommendations. Serum potassium levels will be measured at local laboratories at baseline and 60, 180 minutes and 24 hours. They will perform a visual inspection and a validated semi-quantitative test on each blood sample as an assessment for hemolysis. An independent adjudication committee will adjudicate all major cardiovascular events. The trial will be monitored by a Data Safety Monitoring Board.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 525
• Est. completion date: June 20, 2026
• Est. primary completion date: December 20, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient older than 18 years old

• Patient admitted to the emergency department,

• Patient with local laboratory serum potassium level superior or equal to 5,5 mmol/l,

• Patient who provide written informed consent prior to participation in the study

Exclusion Criteria:

• Hemolysis or thrombocytosis > 106/mm3 or hyperleukocytosis > 105/mm3 on the first blood sample suspecting a pseudohyperkalemia,

• Diabetic ketoacidosis or hyperosmolar hyperglycemic syndrome,

• Pregnant or lactating woman, women with childbearing potential who didn't have effective contraception*,

• Patient expected to require emergency intubation and ventilation,

• Patient expected to require dialysis, diuretics or bicarbonate within the first 60 minutes,

• Patient with heart rhythm disorders or high grade atrioventricular bloc who require urgent medication as soon as admission or serum potassium level result,

• Hypersensitivity to the tested active substance or excipients,

• Acute coronary syndrome,

• Patient not affiliated to a health insurance plan,

• Patient under guardianship, curatorship or safeguard of justice.

• The contraceptives considered as highly effective and acceptable by CTFG recommendations will be considered effective under this protocol. The list of contraceptives considered as highly effective and acceptable by CTFG recommendations is detailed in Appendix 7

Related Conditions & MeSH terms

• Hyperkalemia

Intervention

Drug:
• Salbutamol
10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air) 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period.
• Insulin Aspart
Patients in the experimental group will receive either: 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air); OR 10 units of regular insulin (rapid-acting, insuline asparte, intravenous injection) as an intravenous bolus with 500 ml of 10% dextrose in water administered over a 30-minute period plus 10 mg of salbutamol nebulized in 30 minutes (with oxygen 8 liters per minute or with air). The nurse will start by giving the 10 units of insulin and the dextrose, and then, immediately, she will start the nebulization of salbutamol.

Locations

Country	Name	City	State
France	Agen Hospital	Agen
France	Angers University Hospital	Angers
France	Avicenne University Hospital	Bobigny
France	University Hospital, Clermont-Ferrand	Clermont-Ferrand
France	Louis Mourier Hospital	Colombes
France	University Hospital, Grenoble	Grenoble
France	Nancy University Hospital	Nancy
France	Nantes University Hospital	Nantes
France	Nice University Hospital	Nice
France	La Pitié Salpêtrière University Hospital	Paris
France	Lariboisiere Hospital	Paris
France	Saint Antoine University Hospital	Paris
France	Poitiers University Hospital	Poitiers
France	Rennes University Hospital	Rennes
France	Strasbourg University Hospital	Strasbourg
France	Tours University Hospital	Tours

Sponsors (1)

Lead Sponsor	Collaborator
Nantes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean change in the absolute serum potassium level from baseline to 60 minutes	The primary outcome of our trial will be mean change in the absolute serum potassium level from baseline to 60 minutes (measured in mmol/l), and will be aggregated using median and interquartile.	60 minutes
Secondary	Mean change in the serum potassium level from baseline to 180 minutes and 24 hours		180 minutes and 24 hours
Secondary	Proportion of patients who had a serum potassium level of 4 mmol/l to less than 4.9 mmol/l at 60, 180 minutes and 24 hours		60 minutes, 180 minutes and 24 hours
Secondary	Proportion of patients who require re-treatment or dialysis at 60, 180 minutes and 24 hours		60 minutes, 180 minutes and 24 hours
Secondary	Proportion of patients with adverse effects at 60 and 180 minutes	Proportion of patients with adverse effects at 60 and 180 minutes : Hypokalemia (serum potassium level <3.5 mmol/l and <4 mmol/l); Hypomagnesemia (serum magnesium level of less than 0.58 mmol per liter); Hypoglycemia (serum glucose level < 4.0 mmol/l); Hyperglycemia (serum glucose level > 10.0 mmol/l); Gastrointestinal disorders: i. Diarrhea ii. Nausea iii. Vomiting f. Tachycardia (> 130/min) g. Tremor	60 minutes and 180 minutes
Secondary	Proportion of patients with heart rhythm disorders or high grade atrioventricular bloc that required urgent medication during the first 180 minutes		180 minutes
Secondary	Proportion of patients with electrocardiographic abnormalities, at 60, 180 minutes and 24 hours	Proportion of patients with electrocardiographic abnormalities, at 60, 180 minutes and 24 hours , including: Auricular extrasystoles; Ventricular extrasystoles; Atrioventricular block; QRS Interval Prolongation (> 120 ms); QT interval prolongation (> 500 ms)	60 minutes 180 minutes and 24 hours
Secondary	Proportion of major cardiovascular events at 60, 180 minutes and 24 hours	Proportion of major cardiovascular events at 60, 180 minutes and 24 hours : cardiac arrest; stroke; acute heart failure; complete atrioventricular block with ventricular rate under 30 bpm; ventricular fibrillation; ventricular tachycardia	60minutes 180 minutes and 24 hours